Email
TextThe LILAC study is a two part clinical research study (Part A and Part B) for people with lupus erythematosus and its skin manifestations.
| Sponsored By: | MMG |
| Stipend: | Contact Research Site Directly for Stipend |
| Length of Study: | 40 weeks |
| Research Facility: | Out-Patient |
| Gender: | Both |
| Age: | 18 – 75 |
| Washout Period: | 30 days from Completion Date to Screening |
| Health Condition: | Cutaneous Lupus Erythematosus, systemic lupus erythematosus |
View The Study Website |
|
| More Information: | Part A of the LILAC study will evaluate the efficacy of three different doses of an investigational medication, called BIIB059, in reducing skin disease in people with systemic lupus erythematosus (SLE) with skin activity (also referred to as lupus rash).
Part B of the LILAC study will evaluate the efficacy of an investigational medication, called BIIB059, in reducing skin disease in people with cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE) with skin activity (also referred to as lupus rash). Have active lupus skin disease Are 18 to 75 years old Have been diagnosed with CLE and/or SLE
|
| Report inaccurate listing information by clicking here | |